

MEDICAID POLICY INFORMATION SHEET

Policy Analyst: Vicki Goethals

Phone Number:

Initial ☐

Public Comment ☒

Final ☐

Brief description of policy:

This bulletin removes Medicaid copayments for Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) and HIV post-exposure prophylaxis (PEP) drug products provided through the Medicaid pharmacy benefit.

Reason for policy (problem being addressed):

The removal of pharmacy copayments for HIV PrEP and HIV PEP drug products aligns with both the United States Preventive Services Task Force (USPSTF) Guidelines for prevention of acquisition of HIV and the Centers for Disease Control and Prevention (CDC) Clinical Guidance for HIV PEP.

Budget implication:

- ☒ budget neutral
☐ will cost MDHHS \$, and (select one) budgeted in current appropriation
☐ will save MDHHS \$

Is this policy change mandated per federal requirements?

No, but it is recommended by both the USPSTF Guidelines and CDC Clinical Guidance.

Does policy have operational implications on other parts of MDHHS?

No.

Does policy have operational implications on other departments?

No

Summary of input:

- ☐ controversial (Explain)
☒ acceptable to most/all groups
☐ limited public interest/comment

Supporting Documentation:

State Plan Amendment Required: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No If Yes, please provide status: <input type="checkbox"/> Approved <input checked="" type="checkbox"/> Pending <input type="checkbox"/> Denied Date: Approval Date:	Public Notice Required: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No If yes, Submission Date: 6/11/25
---	---

DRAFT FOR PUBLIC COMMENT Michigan Department of Health and Human Services		
	Project Number: 2534-Pharmacy	Date: August 11, 2025

Comments Due: September 15, 2025
Proposed Effective Date: November 1, 2025
Direct Comments To: Vicki Goethals
E-Mail Address: goethalsv@michigan.gov

Policy Subject: Removal of Pharmacy Copayment for Drugs Used to Prevent Human Immunodeficiency Virus (HIV) (Pre-Exposure Prophylaxis [PrEP] & Post-Exposure Prophylaxis [PEP])

Affected Programs: Medicaid, Healthy Michigan Plan, Maternity Outpatient Medical Services (MOMS)

Distribution: All Providers

Summary: This bulletin removes Medicaid copayments for Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) and HIV post-exposure prophylaxis (PEP) drug products provided through the Medicaid pharmacy benefit.

Purpose: The removal of pharmacy copayments for HIV PrEP and HIV PEP drug products aligns with both the [United States Preventive Services Task Force \(USPSTF\) Guidelines](#) for prevention of acquisition of HIV and the [Centers for Disease Control and Prevention \(CDC\) Clinical Guidance for HIV PEP](#).

Cost Implications: Budget neutral. Section 4106 of the Affordable Care Act established a one percentage point increase in the federal medical assistance percentage (FMAP) for states that provide certain services, including HIV PrEP, without cost-sharing. This FMAP increase will offset the gross cost to the State of Michigan for eliminating copayments for HIV PrEP drug products.

Potential Hearings & Appeal Issues: None

State Plan Amendment Required: Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> If yes, date submitted: Pending	Public Notice Required: Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Submitted date: 6/11/2025
---	--

Tribal Notification: Yes ☒ No ☐ - **Date:** 6/24/2025

THIS SECTION COMPLETED BY RECEIVER

<input type="checkbox"/> Approved	<input type="checkbox"/> No Comments
	<input type="checkbox"/> See Comments Below
<input type="checkbox"/> Disapproved	<input type="checkbox"/> See Comments in Text

Signature:	Phone Number
-------------------	---------------------

Signature Printed:

Bureau/Administration (please print)	Date
---	-------------

Proposed Policy Draft

Michigan Department of Health and Human Services
Health Services

Distribution: All Providers

Issued: October 1, 2025 (proposed)

Subject: Removal of Pharmacy Copayment for Drugs Used to Prevent Human Immunodeficiency Virus (HIV) (Pre-Exposure Prophylaxis [PrEP] & Post-Exposure Prophylaxis [PEP])

Effective: November 1, 2025 (proposed)

Programs Affected: Medicaid, Healthy Michigan Plan, Maternity Outpatient Medical Services (MOMS)

NOTE: Implementation of this policy is contingent upon approval of a State Plan Amendment by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of service on or after November 1, 2025, no pharmacy copayment will be charged to beneficiaries for drug products used to prevent infection of the Human Immunodeficiency Virus (HIV). The removal of pharmacy copayments for HIV pre-exposure prophylaxis(PrEP) and HIV post-exposure prophylaxis (PEP) drug products aligns with both the [United States Preventive Services Task Force \(USPSTF\) Guidelines](#) for prevention of acquisition of HIV and the [Centers for Disease Control and Prevention \(CDC\) Clinical Guidance for HIV PEP](#).

The Michigan Department of Health and Human Services (MDHHS) is removing these copays to eliminate financial barriers to these types of drugs, increase access to care, and further support Michigan's [Equitable Plan](#), aiming to reduce HIV infections.

Drugs that are exempt from pharmacy copayment requirements will be identified on the Michigan Pharmaceutical Products List (MPPL) as "No" under the "Copay" column. The MPPL can be found at <https://mi.primetherapeutics.com/> >> Provider Portal >> Documents >> Fee-for-Service Drug Coverage.